1/53
Looks like no tags are added yet.
Goals of HIV Prevention
Prescribe safe and effective medication to patients who are HIV negative to reduce risk of acquisition
Provide appropriate medication education and support for medication adherence to patients.
Provie HIV risk reduction support and prevention services
Provide effective contraception to persons with childbearing potential who are taking PrEP and do not wish to become pregnant
Monitor for HIV infection, medication-related adverse events and level of risk behaviors
Reduce risk for HIV-1 infection after non-occupational exposure to blood, genital secretion, and other bodily fluids that may contain HIV
Pre-Exposure Prophylaxis (PrEP)
Fixed dose combination treatments are safe and effective for reducing HIV acquisition in MSM, gay men, and women in HIV sero-different couples.
What patient populations are recommended to receive PrEP
Sexually active adults or adolescents (>/=35kg) having anal or vaginal sex in past 6 months AND have any of the following:
Sexual Partner who is positive for HIV
Certain bacterial STI in past 6 months
History of inconsistent or no condom use with sexual partner
Persons who inject drugs:
With injecting partner who is positive for HIV
Sharing injection Equipment
PrEP regimen
Emtricitabine plus Tenofovir (TAF/TDF)
Who should use Emtricitabine + Tenofovir (Truvada)
Cisgender men or cisgender women: includes persons at risk due to sexual behaviors or injection drug use
Cisgender men or transgender women: includes persons at risk due to sexual behaviors but not studied for cisgender women at risk from receptive vaginal sex. Transgender women risk is due to sex with men.
Dosing for Truvada PrEP (cisgender women + cisgender men)
Emtricitabine 200mg + 300mg TDF PO QD
Dosing for Descovy PrEP (cisgender men or transgender women)
Emtricitabine 200mg + TAF 25mg PO QD
Long Acting Injectable Cabotegravir (CAB-LA)
PrEP option. INSTI
FDA Approved for adults >19 and adolescents 10-19 at risk for HIV-1 (>35kg) who are HIV negative prior to initiation. May be offered as additional prevention for people at substantial ongoing risk of HIV-1
May start with oral CAB (Vocabria) QD for 4 weeks to evaluate tolerability and then start injection on the last day or oral dose or within 3 days of last oral dose.
CAB-LA Dosing and administration (Initiation)
600mg IM x 2 given 4 weeks apart
CAB-LA Dosing and administration (Maintenance)
600mg IM q 8 weeks
CAB-LA missed dose
Planned: if scheduled injection will be missed by >7 days, take oral CAB for up to 2 months. Restart injection on last day of daily oral dose or within 3 days.
LEN-LA
PrEP. Long-acting injectable Lenacapavir. Capsid inhibitor.
FDA approved for adolescents weighing at least 35kg who are at risk of HIV-1 acquisition. Highly effective, may increase adherence
LEN-LA dosing and administration
Day 1: 927mg SC injection plus 600mg by mouth (2×300mg tabs)
Day 2L 600mg by mouth (2×300mg tabs)
Continuation 927mg injection q6 months from the date of last injection, ± 2 weeks
LEN-LA missed dose
Planned: if scheduled injection will be missed by more than 2 weeks, may use oral tablets (300mg PO q7 days) on an interim bases for up to 6 months if needed until injections resume.
Unplanned: if more than 28 weeks have elapsed since the last injection and tablets have not been taken, restart initiating from Day 1 if clinically appropriate
PrEP monitoring
Renal function with use of emtricitabine plus Tenofovir: assess CrCl at baseline and at least annually
HIV Ag/Ab testing:
If daily oral PrEP: q3 months
if CAB-LA: q4 months
if LEN-LA: before each injection as appropriate
Always provide adherence support for medication adherence and access, and education appropriate non-pharmacologic preventative methods
Can patient who just started taking PrEP engage in sexual activity with an HIV positive person
CDC: Takes 7 days of daily use to maximize protection from anal sex, and 21 days for vaginal sex
NHS: Wait 7 days before either sex. If patient wishes to engage before day 7, take 2 tabs 2 hours prior and then 1 tablet QD.
WHO: Says PrEP reaches protection after 7 doses. 4 doses for anal and 7 doses for vaginal
PEP
Post Exposure Prophylaxis
Non-occupational PEP (nPEP)
Applies to patients with sexual, injection drug use, or other non-occupational exposure to HIV.
When is nPEP recommended
When exposure occurred within past 72 hours that presents substantial risk for HIV transmission and the source has HIV without sustained viral suppression or viral suppression in not known.
Case-by-case determination is required when exposure has occurred within past 72 hours that presents substantial risk for HIV transmission but not known whether source has HIV.
Laboratory Assessment and monitoring for nPEP - initial visit
Rapid, lab based Ag/Ab HIV test
If patient has LA PrEP exposure in past 6 months, add diagnostic HIV nucleic acid test
Routine labs: SCr, ALT/AST, HBV, pregnancy testing
Based on clinical situation: HCV, STIs
Laboratory Assessment and monitoring for nPEP - 4-6 weeks post exposure
lab-based Ag/Gb HIV test and diagnostic HIV NAT
4-6
Laboratory Assessment and monitoring for nPEP - 12 weeks post exposure
lab-based Ag/Ab HIV test and diagnostic HIV NAT
Treatment duration for nPEP adults
28 days
Administration of nPEP for adults
With or without food
Spacing of nPEP for ADults
2 hours before or 6 hours after medications with polyvalent cations such as aluminum, calcium, iron, or magnesium. Alternatively calcium and iron can be taken with either nPEP regimen with food
nPEP regimens
Bictegravir 50mg + Emtricitabine 200mg/TAF 25mg PO QD
Dolutegravir 50mg + TAF 25mg or TDF 300mg + Emtricitabine 200mg or lamivudine 300 mg PO QD
nPEP regimen selection
Individualized based on comorbidities, pregnancy, potential for DDIs, previous exposure to ART regimens, history of course of HIV exposure, and factors that may influence adherence
Factors that may impact adherence
Pill burden
Dosing Frequency
Formulation
Side effects
cost
Access
nPEP to PrEP
Immediate transition to PrEP at the completion of nPEP may be beneficial for persons with anticipated repeat or ongoing potential exposures to HIV.
Occupational PEP for Healthcare Personnel
Workplaces have standard precautions including appropriate personal protective equipment to prevent HIV exposure from blood, tissue, specific bodily fluids, contaminated medical supplies and equipment, and/or contaminated environmental surfaces.
Need to determine whether source of exposure is positive for HIV and initiate PEP as soon as possible.
Initiation of oPEP
Initiate oPEP as soon as possible, up to 72 hours following exposure. After 72 hours consider initiation after consulting with expert, if exposure is though to present high risk of transmission. Determine HIV status of source whoever possible but do not delay initiation of oPEP while waiting.
Preferred oPEP regimens
Bictegravir 50mg + Emtricitabine 200mg/TAF 25mg PO QD
Dolutegravir 50mg + TAF 25mg or TDF 300mg + Emtricitabine 200mg or lamivudine 300 mg PO QD
Treatment duration of oPEP
28 days
Administration of oPEP
With or without food
Spacing of oPEP
2 hours before or 6 hours after medications with polyvalent cations such as aluminum, calcium, iron, and/or magnesium iron. Alternatively, calcium and iron can be taken with either nPEP regimen with food.
Goals of HIV-1 Treatment
Reduce HIV associated morbidity and prolong duration and quality of survival
Restore and preserve immunologic function
Undetectable viral load/viral suppression (HIV RNA)
Reduce risk of sexual transmission of HIV-1
Reduce risk of perinatal transmission of HIV-1
What is considered to be undetectable or untransmittable viral load
<200 copies/mL
What is considered to be virologically suppressed
<50 copies/mL
When is the initiation of ART recommended
For all persons with HIV, regardless of CD4 count, to reduce morbidity and mortality associated with HIV infection and to prevent transmission to others. Initiate ASAP after diagnosis to increase uptake of ART and improve viral suppression.
How to prevent Sexual transmission at Initiation of ART
Maintain HIV RNA <200 copies to prevent sexual transmission
At initiation of ART use another form of protection for at least 6 months until suppression of viral load is confirmed. Remind patients that an HIV viral load <200 does not prevent other STI transmission/acquisition
PLWH who rely on ART
Must maintain high levels of adherence and should be aware that transmission is possible during period of poor adherence or treatment interruption
ART regimen options for patients without history of CAB-LA use for PrEP
Bictegravir/TAF/Emtricitabine
Dolutegravir/Tenofovir/Emtricitabine or lamivudine
Dolutegravir/lamivudine
Dolutegravir/lamivudine ART counter indications
Patients with HBV co-infection
Unknown HBV serostatus
Without results from genotypic resistance testing for reverse transcriptase
Planning rapid initiation of ART
ART regimen for patients with history of CAB-LA for PrEP
Should first perform INSTI genotypic resistance testing
Darunavir/Cobicistat/Tenofovir/Emtricitabine or Lamivudine
Reasons to optimize ART is patients with viral suppression
Simplify a regimen by reducing pill burden or dosing frequency
Enhance tolerability and decrease toxicities
Prevent or mitigate drug-drug interaction
Eliminate food requirement with administration of ART
Switch to long-acting injectable regimen for convenience
Allow optimal use during pregnancy
Reduce costs of therapy
Bictegravir/Lenacapavir (Bixlenvo)
Approved for patients with HIV-1 who are virologically suppressed based on HIV RNA less than 50 copies on a stable regimen with no concerns for resistance to either agent in the 2-drug combination .
Bictegravir/Lenacapavir (Bixlenvo) renal impairment
no dosage adjustment needed if CrCl >15mL/min no data for <15
Bictegravir/Lenacapavir (Bixlenvo) hepatic impairment
no dosage adjustment needed for child-pugh A or B
No data for C
Assessment for virologic failure
ART adherence, interactions with other drugs or food, drug tolerability, trends in HIV RNA and CD4 count, ART history, current drug resistance test results.
Drug resistance test
Perform while patient is taking failing regimen or within 4 weeks of DC non-long acting forms of ART regimen to best evaluate resistance mutations
If virologic failure occurs what should the new regimen consist
Two fully active drugs if at least one has high resistance barrier (like a second generation INSTI or boosted protease inhibitor)
What should a patient do if they are experiencing Virologic failure
They should not DC or interrupt ART. DC or brief interruption may lead to rapid increase in viral load, decrease in CD4 count, and/or clinical progression of HIV-1
Promoting adherence
Patients must be committed to lifelong adherence
Assess patients for clinical and/or psychological factors that may interfere with timely initiation of ARV and/or adherence
Assess barriers such as medication access, cost, and health literacy
Evaluate eligibility for single-pill complete regimens
Cost and Coverage Considerations
Consider out of pocket costs for PLWH when selecting regimens.
Insurance and prescription drug coverage can directly impact clinical outcomes for PLWH and lapses in coverage may result in lapses in viral suppression.
Collaborate with healthcare team and patient/caregivers to modify ART regimens if costs/coverage present barriers to initiation, adherence, or continuation of ART.
Modification of ART should not compromise virologic efficacy or long-term treatment outcomes